Clinical trial
A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00102336 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 7, 2005
- Completion date
- April 1, 2007
- Enrollment
- 62 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
idiopathic thrombocytopenic purpura, thrombocytopenia